

## Press release from the Extra General Meeting of Paxman AB (publ)

PAXMAN's EGM was held today in Karlshamn. Almost 53,35 % of all issued shares were represented at the meeting.

Paxman AB (publ) held its Extra General Meeting on 8 April 2025 in Karlshamn. At the meeting, Peter Mattisson was elected Chairman and Roger Johansson was appointed to verify the minutes. The EGM approved the agenda, established the voting list, and confirmed that the notice of the meeting had been duly issued. In accordance with the Board's proposal, the EGM resolved to authorize the Board to, on one or more occasions until the next GM, decide on a directed share issue of up to 2,476,207 shares, with the possibility of payment by contribution in kind within the framework of the public takeover offer to the shareholders of Dignitana AB. The minutes from the meeting are available on the company's website https://www.paxman.se/investor-centre/corporate-governance/?lang=en.

## Contacts

Richard Paxman, CEO Tel: +44 7968 020641 Email: richard@paxmanscalpcooling.com www.paxman.se

## About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 6,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK), Houston, Texas (US) and Toronto, Ontario (CA).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser.

## Attachments

Press release from the Extra General Meeting of Paxman AB (publ)